Monitoring for and Characterizing Crizotinib Progression: A Chart Review of ALK-Positive Non-Small Cell Lung Cancer Patients
Crossref DOI link: https://doi.org/10.1007/s12325-017-0551-6
Published Online: 2017-06-03
Published Print: 2017-07
Update policy: https://doi.org/10.1007/springer_crossmark_policy
Bendaly, Edmond
Dalal, Anand A.
Culver, Kenneth
Galebach, Philip
Bocharova, Iryna
Foster, Rebekah
Sasane, Medha
Macalalad, Alexander R.
Guérin, Annie
Funding for this research was provided by:
Novartis Pharmaceuticals Corporation
License valid from 2017-06-03